This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n9http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q93075344
rdf:type
wikibase:Item
schema:description
wetenschappelijk artikel artículu científicu espublizáu n'agostu de 2019 наукова стаття, опублікована 31 серпня 2019 scientific article published on 31 August 2019 article scientifique publié en 2019
p:P577
wds:Q93075344-03528844-41FC-4D7C-861D-6DE1BC994E56
wdt:P577
2019-08-31T00:00:00Z
p:P2093
wds:Q93075344-E4FEC811-87B0-4D39-80E7-F04A9388BF6F wds:Q93075344-65474C73-4BF4-4541-8030-23E770458764 wds:Q93075344-354050EB-EA40-479E-8738-49E6CA0412F1
wdt:P2093
Daniel Muñoz Juan Carlos Morales Rafael de la Torre
rdfs:label
Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial
skos:prefLabel
Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial
schema:name
Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial
p:P50
wds:Q93075344-490F5308-6422-45D4-B2E6-19F33DB2F3E9 wds:Q93075344-503F2C9A-8662-4B33-965A-632E12CBF9E3 wds:Q93075344-55B38BD2-4460-416F-A43E-64B1E0EB140E wds:Q93075344-2F36C4CE-618E-488E-9120-8B50DE6B39FD wds:Q93075344-44013B4B-7510-4A2D-8BF8-9E2E83D4CA4F wds:Q93075344-99233E14-873C-4553-A151-6FE7B5BCAE39 wds:Q93075344-E727B982-F6F2-41A7-A63A-6EB202189A95 wds:Q93075344-A81416BB-CF7D-4485-95CD-B6E95B3FBDFD wds:Q93075344-D4654652-9C54-4E75-AF36-5AE6938E5641 wds:Q93075344-D851B188-CF1A-4980-A82B-46C400B02A39 wds:Q93075344-782546A4-7B3D-4672-89CE-740118076AE8 wds:Q93075344-E4B3E3CA-17D6-4673-8365-7F7BB4BD77A8 wds:Q93075344-0BDC3F23-E964-4DDD-8284-271EA4DB1245
wdt:P50
wd:Q117281651 wd:Q47140932 wd:Q38543991 wd:Q96759878 wd:Q63986076 wd:Q42841081 wd:Q60463126 wd:Q87843490 wd:Q43251771 wd:Q117281649 wd:Q117281650 wd:Q117281647 wd:Q117281648
p:P1476
wds:Q93075344-32121556-1115-4AFA-B7E5-D9CB53D8A375
wdt:P1476
Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial
p:P304
wds:Q93075344-6629BE17-AE2F-4D83-B358-6651B4B98153
wdt:P304
471-481
p:P31
wds:Q93075344-01526EFC-48FA-4B76-9E6A-3DF0A51897BE
wdt:P31
wd:Q13442814
p:P698
wds:Q93075344-96146DFC-FE6E-438C-97F6-810C1AFB494D
wdtn:P698
n12:31479717
wdt:P698
31479717
p:P1433
wds:Q93075344-5BBDDF6C-0C1A-4DFB-8551-60A48A150933
wdt:P1433
wd:Q5500023
p:P478
wds:Q93075344-C8387075-EB34-42DE-9686-4BD61846CCB9
wdt:P478
143
p:P356
wds:Q93075344-D9CA411F-FFDD-4BC1-82CE-5FC7F5E3D3BC
wdtn:P356
n9:J.FREERADBIOMED.2019.08.032
wdt:P356
10.1016/J.FREERADBIOMED.2019.08.032